Trimarchi Thomas 4

What Happened

• Thomas Trimarchi, President and Chief Financial Officer of BridgeBio Pharma, was granted 59,041 restricted stock units (RSUs) on 2026-03-18. The award was reported as an "A" (award/acquisition) transaction at $0.00 (no cash paid at grant). Each RSU is a contingent right to receive one share of common stock on vesting.

Key Details

• Transaction date: 2026-03-18; Filing date/accession: 2026-03-20 (Form 4 filed within the typical 2-business-day window).
• Grant size and price: 59,041 RSUs; reported acquisition price $0.00 (grant).
• Vesting: RSUs vest as to 1/16th of the underlying shares on May 16, 2026, and 1/16th each quarter thereafter until fully vested, subject to continued service. RSUs have no expiration date. (Footnotes F1, F2)
• Shares owned after transaction: Not reported in the excerpt provided.
• Transaction code: A = Award/Grant of equity (not a purchase or sale).

Context

• RSUs are a form of deferred equity compensation; they do not transfer actual shares until they vest. This grant does not represent an open‑market purchase or sale and should not be interpreted as an immediate cash investment by the insider. Any shares issued on vesting or any later sale of those shares will generate separate filings.